Cell Therapeutics’s “Positive” Rating Reaffirmed at Wells Fargo & Co. (CTIC)
Cell Therapeutics (NASDAQ:CTIC)‘s stock had its “positive” rating reaffirmed by Wells Fargo & Co. in a research note issued on Monday, AR Network reports.
Cell Therapeutics (NASDAQ:CTIC) traded up 18.24% on Monday, hitting $1.88. 8,959,772 shares of the company’s stock traded hands. Cell Therapeutics has a one year low of $0.97 and a one year high of $1.80. The stock’s 50-day moving average is $1.2 and its 200-day moving average is $1.17. The company’s market cap is $202.5 million. Cell Therapeutics also was the recipient of some unusual options trading on Friday. Stock traders purchased 10,275 put options on the company. This represents an increase of 1,565% compared to the average daily volume of 617 put options.
In other Cell Therapeutics news, CEO James A. Bianco unloaded 130,551 shares of Cell Therapeutics stock in a transaction dated Monday, September 23rd. The shares were sold at an average price of $1.50, for a total transaction of $195,826.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Cell Therapeutics, Inc develops, acquires and commercializes treatments for cancer. It focuses on building a biopharmaceutical company with a diversified portfolio of oncology drugs.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.